An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
{{output}}
Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre... ...
